Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
14 July 2000Website:
http://www.cassavasciences.comNext earnings report:
02 August 2024Last dividends:
13 December 2012Next dividends:
N/APrice
regular market | 7 min agoDividend
Analysts recommendations
Institutional Ownership
SAVA Latest News
Cassava Sciences SAVA has engaged the U.S. Department of Justice (DOJ) and the U.S. Securities and Exchange Commission (SEC) amid ongoing investigations into the company and two senior employees.
Shares of Cassava Sciences (NASDAQ: SAVA ), which has an Alzheimer's drug candidate called simufilam, fell 35% on June 28 and another 13% over the weekend. This move in SAVA stock comes after a key science advisor was charged with defrauding the National Institutes of Health (NIH).
A former consultant to Cassava was indicted for alleged fraud related to NIH grants. Cassava received some federal funding related to these grants.
Shares of biotech company Cassava Sciences Inc. plummeted on Friday after a federal grand jury indicted a onetime science advisor to Cassava and charged him with falsifying data to obtain millions of dollars in government funds — the latest drama for a company that has faced questions over its efforts to develop an experimental Alzheimer's disease drug.
A federal indictment accuses a Cassava Sciences advisor of faking data to secure NIH grants. The company also faces shareholder suits.
AUSTIN, Texas, June 28, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), reported it has learned today that a federal grand jury returned an indictment charging Hoau-Yan Wang for allegedly defrauding the U.S. National Institutes of Health (NIH). Hoau-Yan Wang was a tenured medical professor at a public university's medical school as well as a former paid science advisor to Cassava Sciences.
After reaching an important support level, Cassava Sciences, Inc. (SAVA) could be a good stock pick from a technical perspective. SAVA recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced plans to present a virtual oral presentation at the International Conference on Alzheimer's and Parkison's Disease (AD/PD 2024) taking place in Lisbon, Portugal from March 5-9, 2024.
Cassava Sciences stock is down due to questions about some of its research. A lot is riding on its late-stage clinical trials to produce favorable data.
In the biotechnology sector, Cassava Sciences (NADSAQ: SAVA ) remains one of the top clinical-stage companies that investors are watching. Over the past one year, SAVA stock is down by less than 20% but up nearly 9% for the past six months.
- 1(current)
- 2
What type of business is Cassava Sciences?
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
What sector is Cassava Sciences in?
Cassava Sciences is in the Healthcare sector
What industry is Cassava Sciences in?
Cassava Sciences is in the Biotechnology industry
What country is Cassava Sciences from?
Cassava Sciences is headquartered in United States
When did Cassava Sciences go public?
Cassava Sciences initial public offering (IPO) was on 14 July 2000
What is Cassava Sciences website?
https://www.cassavasciences.com
Is Cassava Sciences in the S&P 500?
No, Cassava Sciences is not included in the S&P 500 index
Is Cassava Sciences in the NASDAQ 100?
No, Cassava Sciences is not included in the NASDAQ 100 index
Is Cassava Sciences in the Dow Jones?
No, Cassava Sciences is not included in the Dow Jones index
When does Cassava Sciences report earnings?
The next expected earnings date for Cassava Sciences is 02 August 2024